India cancels licenses of 18 pharma companies due to spurious medicines

14 April 2023

The Indian government has taken strict action against 34 companies in what is being termed the biggest crackdown against pharmaceutical companies manufacturing substandard drugs. Licenses of 18 pharma companies have been cancelled, in what would serve as a clear warning to erring pharmaceutical companies.

An initiative to check the production of substandard medicines was launched earlier this year by state drug regulators. Inspection is currently in progress across the country in the second round.

A joint inspection of 203 pharmaceutical companies was conducted as part of this special drugs inspection drive.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK